Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Takeda’s Alogliptin Falls Prey To FDA Slowdown

Oct 10 2008

• By Emily Hayes

Related Content

The Longest Review: Inside Ovation’s Wait For Sabril

Aug 27 2008

FDA New Drug Review Performance May Miss Lowered Expectations – Jenkins

Sep 29 2008

Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market

Jan 04 2008

FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs

Mar 17 2008

FDA Should Require Cardiovascular Outcomes Trials For All Type 2 Diabetes Drugs, Panel Says

Jul 02 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window